Cargando…

Secondary lymphoblastic leukemia occurring 38 months after the primary diagnosis of multiple myeloma: A case report

Multiple myeloma (MM) is a malignant plasma cell neoplasm characterized by the accumulation of plasma cells in the bone marrow, the subsequent destruction of bone and organ dysfunction. The present study describes the case of a 66-year-old male patient who presented with the typical clinical manifes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Junxun, Zhan, Jieyu, Zhang, Fan, Ye, Zhuangjian, Ouyang, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950900/ https://www.ncbi.nlm.nih.gov/pubmed/27446359 http://dx.doi.org/10.3892/ol.2016.4728

Ejemplares similares

Multiple myeloma secondary to acute lymphoblastic leukemia: A case report
por: Hu, Tonglin, et al.
Publicado: (2019)

Lenalidomide induced secondary Acute Lymphoblastic Leukemia in a Multiple Myeloma patient: A case-report
por: Khan, Dr. Saqib Raza, et al.
Publicado: (2022)

Therapy-related B-lymphoblastic leukemia after multiple myeloma
por: Kallen, Michael E., et al.
Publicado: (2022)

Secondary acute lymphoblastic leukaemia in a multiple myeloma patient
por: Piszcz, Jaroslaw, et al.
Publicado: (2013)

The Diagnostic Efficacy of Age-Adjusted D-Dimer Cutoff Value and Pretest Probability Scores for Deep Venous Thrombosis
por: Li, Junxun, et al.
Publicado: (2019)

Clinical Characteristics and Prognosis of Secondary Acute Lymphoblastic Leukemia in Patients with Multiple Myeloma during Long-Term Thalidomide Maintenance
por: Liu, Junru, et al.
Publicado: (2023)

Acute B Lymphoblastic Leukemia Developing in Patients with Multiple Myeloma: Presentation of Two Cases
por: Mei, Jiang, et al.
Publicado: (2019)

Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma
por: Parrondo, Ricardo D., et al.
Publicado: (2022)

Delayed Diagnosis of Cardiac Amyloidosis Secondary to Multiple Myeloma
por: Qatanani, Ahmad, et al.
Publicado: (2021)

An adult B-cell precursor acute lymphoblastic leukemia with multiple secondary cytogenetic aberrations
por: AL-Achkar, Walid, et al.
Publicado: (2014)

Diagnosis and Subclassification of Acute Lymphoblastic Leukemia
por: Chiaretti, Sabina, et al.
Publicado: (2014)

Overexpression of SLC25A38 protein on acute lymphoblastic leukemia cells
por: CHEN, HUAYING, et al.
Publicado: (2014)

CD34 and CD38 are prognostic biomarkers for acute B lymphoblastic leukemia
por: Jiang, Zhiwu, et al.
Publicado: (2016)

Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia
por: Zatula, Alexey, et al.
Publicado: (2016)

Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia
por: Allegra, Alessandro, et al.
Publicado: (2021)

The Anti-CD38 Antibody Therapy in Multiple Myeloma
por: Petrucci, Maria Teresa, et al.
Publicado: (2019)

CD38-Directed Therapies for Management of Multiple Myeloma
por: Hashmi, Hamza, et al.
Publicado: (2021)

Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma
por: Ching, Travers, et al.
Publicado: (2020)

Dyslipidemia at diagnosis of childhood acute lymphoblastic leukemia
por: Mogensen, Pernille Rudebeck, et al.
Publicado: (2020)

Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features
por: Khan, Abdullah M., et al.
Publicado: (2018)

Secondary Plasma Cell Leukemia in a Recurrent Multiple Myeloma: Rare Case Scenario
por: Inamdar, Arati A, et al.
Publicado: (2020)

Can CD34(+)CD38(−) lymphoblasts, as likely leukemia stem cells, be a prognostic factor in B-cell precursor acute lymphoblastic leukemia in children?
por: Stolpa, Weronika, et al.
Publicado: (2023)

CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
por: Morandi, Fabio, et al.
Publicado: (2018)

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
por: Saltarella, Ilaria, et al.
Publicado: (2020)

Anti CD38 monoclonal antibodies for multiple myeloma treatment
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Targeted treatment of T-cell acute lymphoblastic leukemia: latest updates from the 2022 ASH Annual Meeting
por: Xu, Jieyu, et al.
Publicado: (2023)

Corrigendum to “Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features”
por: Khan, Abdullah M., et al.
Publicado: (2019)

Treatment-Associated Acute Lymphoblastic Leukemia Following Autologous Hematopoietic Stem Cell Transplant and Lenalidomide Maintenance in Patients With Multiple Myeloma
por: Crosby, James, et al.
Publicado: (2022)

Renal involvement at diagnosis of pediatric acute lymphoblastic leukemia
por: Prada Rico, Mayerly, et al.
Publicado: (2020)

Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia
por: Inaba, Hiroto, et al.
Publicado: (2021)

Heterogeneity of CD34 and CD38 expression in acute B lymphoblastic leukemia cells is reversible and not hierarchically organized
por: Jiang, Zhiwu, et al.
Publicado: (2016)

Acute Lymphoblastic Leukemia Presented as Multiple Breast Masses
por: Bayrak, Ilkay Koray, et al.
Publicado: (2009)

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
por: van de Donk, Niels W.C.J., et al.
Publicado: (2018)

Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies
por: Wu, Hao-Tian, et al.
Publicado: (2022)

Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure
por: Alhuraiji, Ahmad, et al.
Publicado: (2017)

Phenotyping and Target Expression Profiling of CD34(+)/CD38(−) and CD34(+)/CD38(+) Stem- and Progenitor cells in Acute Lymphoblastic Leukemia
por: Blatt, Katharina, et al.
Publicado: (2018)

Two Rare Cases of Therapy-Related Acute Lymphoblastic Leukemia in Patients With Plasma Cell Myeloma
por: Lee, Hye-Young, et al.
Publicado: (2019)

EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma
por: Chemlal, Djamila, et al.
Publicado: (2023)

The Coexistence of Chronic Lymphocytic Leukemia and Multiple Myeloma
por: Hangül, Ceren, et al.
Publicado: (2019)

The Clinical Diagnosis of Multiple Myeloma
por: Ainley, N. J.
Publicado: (1954)

Cannot write session to /tmp/vufind_sessions/sess_j2pp129ahktg8eu79ud098u9dt